Vnitr Lek 2016, 62(Suppl 3):40-44

Thyroid cancer in children and adolescents and its molecular genetic background

Běla Bendlová1,*, Vlasta Sýkorová1, Eliška Václavíková1, Josef Včelák1, Rami Katra2, Pavla Sýkorová3, Petr Vlček3, Šárka Dvořáková1
1 Oddělení molekulární endokrinologie Endokrinologického ústavu, Praha
2 Klinika ušní, nosní a krční 2. LF UK a FN v Motole, Praha
3 Klinika nukleární medicíny a endokrinologie 2. LF UK a FN v Motole, Praha

Thyroid cancer is the main endocrine malignancy. Its incidence is steadily growing and what is alarming is its increase in children and adolescent population. Pediatric thyroid carcinomas differ from the adult ones in phenotype as well as in genetics. These carcinomas tend to be clinically more aggressive, with more frequent local and distant metastases. However, their long-term prognosis is better in comparison with the adult thyroid cancers. Due to the rarity of the disease, there is lack of data on genetic changes in this age group. Knowledge on the genetic background of thyroid cancer in children will help to precise diagnosis and prognosis of the disease and to personalized treatment.

Keywords: adolescents; carcinoma; gene; genetics; children; mutation; next generation sequencing; thyroid

Received: August 29, 2016; Accepted: September 13, 2016; Published: June 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bendlová B, Sýkorová V, Václavíková E, Včelák J, Katra R, Sýkorová P, et al.. Thyroid cancer in children and adolescents and its molecular genetic background. Vnitr Lek. 2016;62(Supplementum 3):40-44.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Greenlee RT, Hill-Harmon MB, Murray T et al. Cancer statistics, 2001. CA Cancer J Clin 2001; 51(1): 15-36. Erratum in CA Cancer J Clin 2001; 51(2): 144. Go to original source... Go to PubMed...
    2. Dušek L, Mužík J, Kubásek M et al. Epidemiology of Malignant Tumours in the Czech Republic [online]. Masaryk University (Czech Republic): 2005. Dostupné z WWW: <http://www.svod.cz>. Version 7.0 (2007). [18.08.2016].
    3. Miyakawa M. Radiation exposure and the risk of pediatric thyroid cancer. Clin Pediatr Endocrinol 2014; 23(3): 73-82. Go to original source... Go to PubMed...
    4. Fridman M, Savva N, Krasko O et al. Initial presentation and late results of treatment of post-chernobyl papillary thyroid carcinoma in children and adolescents of belarus. J Clin Endocrinol Metab 2014; 99(8): 2932-2941. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2013-3131>. Go to original source... Go to PubMed...
    5. Yamashita S, Suzuki S. Risk of thyroid cancer after the Fukushima nuclear power plant accident. Respir Investig 2013; 51(3): 128-133. Dostupné z DOI: <http://dx.doi.org/10.1016/j.resinv.2013.05.007>. Go to original source... Go to PubMed...
    6. Cordioli MI, Moraes L, Cury AN et al. Are we really at the dawn of understanding sporadic pediatric thyroid carcinoma? Endocr Relat Cancer 2015; 22(6): R311-R324. Dostupné z DOI: <http://dx.doi.org/10.1530/ERC-15-0381>. Go to original source... Go to PubMed...
    7. Nikiforov YE, Biddinger PW, Thompson LD (eds). Diagnostic Pathology and Molecular Genetics of the Thyroid. Lippincott Williams & Wilkins 2009. ISBN 978-0781774598.
    8. Astl J, Chovanec M, Lukeš P et al. Thyroid carcinoma surgery in children and adolescents - 15 years experience surgery of pediatric thyroid carcinoma. Int J Pediatr Otorhinolaryngol 2014; 78(7): 990-994. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijporl.2014.03.005>. Go to original source... Go to PubMed...
    9. Avram AM, Shulkin BL. Thyroid cancer in children. J Nucl Med 2014; 55(5): 705-707. Dostupné z DOI: <http://dx.doi.org/10.2967/jnumed.113.136077>. Go to original source... Go to PubMed...
    10. Millar S, Bradley L, Donnelly DE et al. Familial pediatric endocrine tumors. Oncologist 2011; 16(10): 1388-1396. Dostupné z DOI: <http://dx.doi.org/10.1634/theoncologist.2011-0120>. Go to original source... Go to PubMed...
    11. Francis G, Waguespack SG, Bauer AJ et al. Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Pediatric Thyroid Cancer. Thyroid 2015; 25(7): 716-759. Dostupné z DOI: <http://dx.doi.org/10.1089/thy.2014.0460>. Go to original source... Go to PubMed...
    12. Markovina S, Grigsby PW, Schwarz JK et al. Treatment approach, surveillance, and outcome of well-differentiated thyroid cancer in childhood and adolescence. Thyroid 2014; 24(7): 1121-1126. Dostupné z DOI: <http://dx.doi.org/10.1089/thy.2013.0297>. Go to original source... Go to PubMed...
    13. Tran Cao HS, Johnston LE, Chang DC et al. A critical analysis of the American Joint Committee on Cancer (AJCC) staging system for differentiated thyroid carcinoma in young patients on the basis of the Surveillance, Epidemiology, and End Results (SEER) registry. Surgery 2012; 152(2): 145-151. Dostupné z DOI: <http://dx.doi.org/10.1016/j.surg.2012.02.015>. Go to original source... Go to PubMed...
    14. Papp S, Asa SL. When thyroid carcinoma goes bad: a morphological and molecular analysis. Head Neck Pathol 2015; 9(1): 16-23. Dostupné z DOI: <http://dx.doi.org/10.1007/s12105-015-0619-z>. Go to original source... Go to PubMed...
    15. Viola D, Valerio L, Molinaro E et al. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. Endocr Relat Cancer 2016; 23(4): R185-R205. Dostupné z DOI: <http://dx.doi.org/10.1530/ERC-15-0555>. Go to original source... Go to PubMed...
    16. Tavares C, Melo M, Cameselle-Teijeiro JM et al. Endocrine tumours: Genetic predictors of thyroid cancer outcome. Eur J Endocrinol 2016; 174(4): R117-R126. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-15-0605>. Go to original source... Go to PubMed...
    17. Wu C, Schwartz JM, Brabant G et al. Molecular profiling of thyroid cancer subtypes using large-scale text mining. BMC Med Genomics 2014; 7(Suppl 3): 53. <http://dx.doi.org/10.1186/1755-8794-7-S3-S3>. Go to original source... Go to PubMed...
    18. Nikiforova MN, Wald AI, Roy S et al. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab 2013; 98(11): E1852-E1860. <http://dx.doi.org/10.1210/jc.2013-2292>. Go to original source... Go to PubMed...
    19. Xing M, Alzahrani AS, Carson KA et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013; 309(14): 1493-1501. <http://dx.doi.org/10.1001/jama.2013.3190>. Go to original source... Go to PubMed...
    20. Sykorova V, Dvorakova S, Ryska A et al. BRAFV600E Mutation in the Pathogenesis of a Large Series of Papillary Thyroid Carcinoma in Czech Republic. J Endocrinol Invest 2010; 33(5): 318-324. <http://dx.doi.org/10.3275/6722>. Go to original source... Go to PubMed...
    21. Xing M, Alzahrani AS, Carson KA et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol 2015; 33(1): 42-50. <http://dx.doi.org/10.1200/JCO.2014.56.8253>. Go to original source... Go to PubMed...
    22. Dvorakova S, Sykorova V, Vaclavikova E et al. A 3-bp Deletion VK600-1E in the BRAF Gene Detected in a Young Woman with Papillary Thyroid Carcinoma. Endocr Pathol 2015; 26(4): 309-314. <http://dx.doi.org/10.1007/s12022-015-9387-2>. Go to original source... Go to PubMed...
    23. Leeman-Neill RJ, Brenner AV, Little MP et al. RET/PTC and PAX8/PPARγ chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics. Cancer 2013; 119(10): 1792-1799. <http://dx.doi.org/10.1002/cncr.27893>. Go to original source... Go to PubMed...
    24. Halkova T, Dvorakova S, Vaclavikova E et al. A novel RET/PTC variant detected in a pediatric patient with papillary thyroid cancer without ionization history. Hum Pathol 2015; 46(12): 1962-1969. <http://dx.doi.org/10.1016/j.humpath.2015.08.013>. Go to original source... Go to PubMed...
    25. Armstrong MJ, Yang H, Yip L et al. PAX8/PPARγ rearrangement in thyroid nodules predicts follicular-pattern carcinomas, in particular the encapsulated follicular variant of papillary carcinoma. Thyroid 2014; 24(9): 1369-1374. <http://dx.doi.org/10.1089/thy.2014.0067>. Go to original source... Go to PubMed...
    26. Picarsic JL, Buryk MA, Ozolek J et al. Molecular Characterization of Sporadic Pediatric Thyroid Carcinoma with the DNA/RNA ThyroSeq v2 Next-Generation Sequencing Assay. Pediatr Dev Pathol 2016; 19(2): 115-122. <http://dx.doi.org/10.2350/15-07-1667-OA.1>. Go to original source... Go to PubMed...
    27. Prasad ML, Vyas M, Horne MJ et al. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Cancer 2016; 122(7): 1097-1107. <http://dx.doi.org/10.1002/cncr.29887>. Go to original source... Go to PubMed...
    28. Beadling C, Wald AI, Warrick A et al. A Multiplexed Amplicon Approach for Detecting Gene Fusions by Next-Generation Sequencing. J Mol Diagn 2016; 18(2): 165-175. <http://dx.doi.org/10.1016/j.jmoldx.2015.10.002>. Go to original source... Go to PubMed...
    29. Lee SR, Jung CK, Kim TE et al. Molecular genotyping of follicular variant of papillary thyroid carcinoma correlates with diagnostic category of fine-needle aspiration cytology: values of RAS mutation testing. Thyroid 2013; 23(11): 1416-1422. <http://dx.doi.org/10.1089/thy.2012.0640>. Go to original source... Go to PubMed...
    30. Eszlinger M, Niedziela M, Typlt E et al. Somatic mutations in 33 benign and malignant hot thyroid nodules in children and adolescents. Mol Cell Endocrinol 2014; 393(1-2): 39-45. <http://dx.doi.org/10.1016/j.mce.2014.05.023>. Go to original source... Go to PubMed...
    31. Liu R, Xing M. TERT promoter mutations in thyroid cancer. Endocr Relat Cancer 2016; 23(3): R143-R155. <http://dx.doi.org/10.1530/ERC-15-0533>. Go to original source... Go to PubMed...
    32. Liu X, Qu S, Liu R et al. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab 2014; 99(6): E1130-E1136. <http://dx.doi.org/10.1210/jc.2013-4048>. Go to original source... Go to PubMed...
    33. Nikiforov YE, Carty SE, Chiosea SI et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer 2014; 120(23): 3627-3634. Dostupné z DOI: <http://dx.doi.org/10.1002/cncr.29038>. Go to original source... Go to PubMed...
    34. [Cancer Genome Atlas Research Network]. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014; 159(3): 676-690. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cell.2014.09.050>. Go to original source... Go to PubMed...
    35. Costa V, Esposito R, Pallante P et al. The "next-generation" knowledge of papillary thyroid carcinoma. Cell Cycle 2015; 14(13): 2018-2021. Dostupné z DOI: <http://dx.doi.org/10.1080/15384101.2015.1049786>. Go to original source... Go to PubMed...
    36. Agrawal N, Jiao Y, Sausen M et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab 2013; 98(2): E364-E369. Dostupné z DOI: <http://DX.DOI.ORG/10.1210/jc.2012-2703>. Go to original source... Go to PubMed...
    37. Bendlová B, Dvoráková S, Václavíková E et al. Nádory štítné žlázy a Hirschsprungova choroba: desetileté zkušenosti s molekulární genetickou diagnostikou RET proto-onkogenu. Vnitř Lék 2006; 52(10): 926-934. Go to PubMed...
    38. Dvorakova S, Vaclavikova E, Duskova J et al. Exon 5 of the RET proto-oncogene: a newly detected risk exon for familial medullary thyroid carcinoma, a novel germ-line mutation Gly321Arg. J Endocrinol Invest 2005; 28(10): 905-909. Go to original source... Go to PubMed...
    39. Sykorova V, Dvorakova S, Vcelak J et al. Search for new genetic biomarkers in poorly differentiated and anaplastic thyroid carcinomas using next generation sequencing. Anticancer Res 2015; 35(4): 2029-2036.
    40. Malkin D, Nichols KE, Zelley K et al. Predisposition to pediatric and hematologic cancers: a moving target. Am Soc Clin Oncol Educ Book 2014; e44-e55. Dostupné z DOI: <http://dx.doi.org/10.14694/EdBook_AM.2014.34.e44>. Go to original source... Go to PubMed...
    41. Wójcicka A, Kolanowska M, Jażdżewski K. Mechanisms in endocrinology: MicroRNA in diagnostics and therapy of thyroid cancer. Eur J Endocrinol 2016; 174(3): R89-R98. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-15-0647>. Go to original source... Go to PubMed...
    42. Valderrabano P, Zota VE, McIver B et al. Molecular Assays in Cytopathology for Thyroid Cancer. Cancer Control 2015; 22(2): 152-157. Go to original source... Go to PubMed...
    43. Dvorakova S, Vaclavikova E, Sykorova V et al. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas. Mol Cell Endocrinol 2008; 284(1-2): 21-27. Dostupné z DOI: <http://dx.doi.org/10.1016/j.mce.2007.12.016>. Go to original source... Go to PubMed...
    44. Jindrichová S, Vcelák J, Vlcek P et al. Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic. J Endocrinol 2004; 183(2): 257-265. Go to original source... Go to PubMed...
    45. Manwar Hussain MR, Khan A, Ali Mohamoud HS. From genes to health - challenges and opportunities. Front Pediatr 2014; 2: 12. Dostupné z DOI: <http://dx.doi.org/10.3389/fped.2014.00012>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.